Cellectis S.A. (CMVLF)
- Previous Close
2.6000 - Open
2.9600 - Bid --
- Ask --
- Day's Range
2.9600 - 2.9600 - 52 Week Range
0.9500 - 3.5800 - Volume
285 - Avg. Volume
33 - Market Cap (intraday)
301.05M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3700 - Earnings Date May 28, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia; UCART123 to treat acute myeloid leukemia; UCART 20x22 for relapsed or refractory B-Cell non-hodgkin's lymphoma; and cema-cel to treat relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics, Inc.; and joint research and collaboration, and investment agreement with AstraZeneca Holdings B.V., as well as with AstraZeneca Ireland Limited. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
www.cellectis.comRecent News: CMVLF
Performance Overview: CMVLF
Trailing total returns as of 6/6/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CMVLF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CMVLF
Valuation Measures
Market Cap
262.12M
Enterprise Value
207.16M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
34.52
Price/Book (mrq)
2.80
Enterprise Value/Revenue
40.27
Enterprise Value/EBITDA
-3.71
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-19.45%
Return on Equity (ttm)
-78.99%
Revenue (ttm)
12.13M
Net Income Avi to Common (ttm)
-78.42M
Diluted EPS (ttm)
-1.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
122.97M
Total Debt/Equity (mrq)
54.09%
Levered Free Cash Flow (ttm)
-16.77M
Company Insights: CMVLF
CMVLF does not have Company Insights